Carbetocin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Carbetocin: From Postpartum Haemorrhage Prevention to Isotretinoin-Like Syndrome
One-Sentence Summary
Carbetocin is a long-acting synthetic oxytocin analogue used clinically as a uterotonic agent for the prevention of postpartum haemorrhage following caesarean and vaginal delivery. The TxGNN model predicts it may be effective for Isotretinoin-Like Syndrome (score: 99.15%), however there are 0 clinical trials and 0 publications supporting this specific pairing — the mechanistic connection is entirely unestablished and the prediction is likely a knowledge-graph structural artefact.
⚠️ Notable finding across all 10 predictions: Prader-Willi syndrome (rank 3, score 98.99%) is the only candidate with a biologically coherent rationale — OTR signalling deficits are a documented feature of this condition, and levo-carbetocin (RG7314) has previously entered Phase 2 trials in PWS. This warrants a separate, dedicated evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prevention of postpartum haemorrhage (uterotonic use; not registered in Singapore) |
| Predicted New Indication | Isotretinoin-Like Syndrome |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Carbetocin is a structural analogue of oxytocin with a prolonged duration of action. It acts as an agonist at the oxytocin receptor (OTR), inducing sustained uterine contractions. Compared to native oxytocin, structural modifications at its N-terminus and C-terminus make it resistant to enzymatic degradation, resulting in a half-life approximately four to ten times longer. This property underpins its clinical role in uterotonic prophylaxis after delivery.
Isotretinoin-like syndrome (retinoic acid embryopathy) is a congenital malformation syndrome caused by gestational exposure to retinoids. The affected pathways involve retinoic acid receptor (RAR/RXR) signalling and neural crest cell development — neither of which has any known intersection with the oxytocin/OTR axis. There is no pharmacological, genetic, or epidemiological basis linking OTR agonism to isotretinoin-related teratogenicity.
The TxGNN model's high score for this pairing most likely reflects shared comorbidity structures or co-occurrence patterns within the knowledge graph rather than a genuine mechanistic relationship. Without an articulated biological hypothesis connecting these two, this prediction does not meet the threshold for further investment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Carbetocin is not currently registered with HSA (Health Sciences Authority) Singapore. No product authorisations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score (99.15%), there is no established mechanistic pathway connecting oxytocin receptor agonism to isotretinoin-like syndrome, and the evidence base is entirely absent (L5 — model prediction only). Proceeding without any biological hypothesis or preclinical signal would not be a responsible use of resources.
To proceed, the following is needed:
- Mechanistic hypothesis first: Identify any biological pathway by which OTR agonism could intersect with retinoic acid teratogenicity before committing further resources to this pairing.
- Re-prioritise to Prader-Willi syndrome (rank 3): Open a dedicated evidence pack for the PWS indication. The OTR–PWS mechanistic link is well-documented; cross-validate CARE-PWS (Levo-carbetocin / RG7314) trial data directly against ClinicalTrials.gov, as the current dataset shows 0 trials despite external knowledge indicating a Phase 2 study was conducted.
- Obtain complete safety profile: Download and parse the relevant package insert (EMA SmPC or TFDA monograph) to populate key warnings, contraindications, and special population data (the primary data gap blocking S1 safety assessment).
- Confirm MOA via DrugBank API: Complete the mechanism-of-action record to support any downstream mechanistic analysis for higher-priority candidates.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.